The identification of LY6E as a viable objective for cancer immunotherapy has driven considerable effort. Various antibody candidates are now explored with the purpose of specifically neutralizing LY6E's role and promoting an antitumor response in those affected with multiple malignancies . Hurdles remain in optimizing antibody delivery and mitigat